Literature DB >> 34082513

Oncological Follow-up with 2-[18F]-FDG PET/CT in Li-Fraumeni Syndrome

Marylin Acuña Hernandez1, Iván Fabricio Vega Gonzalez2, Lina López Vélez2, Catalina Melo Arango3.   

Abstract

Li-Fraumeni syndrome is a rare disorder caused by abnormalities of the tumor-suppressor protein P53 gene. We present the case of a 26-years-old female diagnosed with bilateral ductal carcinoma. The genetic panel for breast cancer gene 1 (BRCA1) and BRCA2 mutations was negative and positive heterozygous germline tumor protein P53 gene mutations, considering Li-Fraumeni syndrome. A 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) was used for postsurgical staging to show the right lung hypermetabolic nodule. A lobectomy was accomplished, and histopathology reported pulmonary adenocarcinoma. A year later, oncological follow-up was conducted with 2-[18F]-FDG PET/CT without evidence of abnormalities.

Entities:  

Keywords:  Li-Fraumeni syndrome; fluorodeoxyglucose 18F; positron emission tomography

Year:  2021        PMID: 34082513      PMCID: PMC8185483          DOI: 10.4274/mirt.galenos.2020.33255

Source DB:  PubMed          Journal:  Mol Imaging Radionucl Ther        ISSN: 2146-1414


  2 in total

Review 1.  Li-Fraumeni syndrome: cancer risk assessment and clinical management.

Authors:  Kate A McBride; Mandy L Ballinger; Emma Killick; Judy Kirk; Martin H N Tattersall; Rosalind A Eeles; David M Thomas; Gillian Mitchell
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

2.  (18)F-FDG PET-CT for Surveillance of Brazilian Patients with Li-Fraumeni Syndrome.

Authors:  Sonia Tereza Santos Nogueira; Eduardo Nóbrega Pereira Lima; Amanda França Nóbrega; Ivone Do Carmo Gonçalves Torres; Marcelo Cavicchioli; Pierre Hainaut; Maria Isabel Waddington Achatz
Journal:  Front Oncol       Date:  2015-02-19       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.